Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

What is the Effect of Increased Consumption of Fruit Juice on Exercise Capacity and Inflammatory Biomarkers?

13 de noviembre de 2026 actualizado por: Christopher Tanayan, Northwell Health

Dietary patterns and physical inactivity common in Western societies have been associated with chronic low-grade inflammation and an increased risk of non-communicable health conditions. Fruits and vegetables contain polyphenols and other bioactive compounds that may have antioxidant and anti-inflammatory properties and may influence inflammatory biomarkers.

This study will evaluate the effects of increased consumption of a fruit juice on inflammatory biomarkers and exercise capacity in adults with mildly elevated inflammation. Approximately 40 participants will be randomly assigned to consume one of two fruit juice interventions daily for approximately 2 weeks. Changes in C-reactive protein (CRP) and exercise capacity, assessed using a 6-minute walk test, will be evaluated before and after the intervention and compared between the two groups.

Descripción general del estudio

Descripción detallada

Industrialization and changes in dietary and physical activity patterns have contributed to differences in the health conditions experienced by populations in Western societies. Chronic, non-communicable conditions, many of which are associated with low-grade inflammation, are now major contributors to morbidity and mortality. Dietary patterns characterized by high consumption of refined carbohydrates, sugars, salt, and animal fats and relatively low consumption of fruits, vegetables, fiber, and plant-derived phytochemicals may contribute to an inflammatory state. Similarly, low levels of physical activity have been associated with increased inflammation and elevated inflammatory biomarkers such as C-reactive protein (CRP).

Fruits and vegetables provide fiber, vitamins, minerals, and bioactive compounds including polyphenols. Polyphenols are plant-derived compounds with antioxidant and anti-inflammatory properties that may influence inflammatory processes and other physiological pathways. Increasing consumption of minimally processed plant foods and fruit-derived products may therefore represent a potential approach for increasing intake of these bioactive compounds and examining their relationship with markers of inflammation and physical performance.

This randomized, parallel-group interventional study will evaluate the effects of two fruit juice interventions on inflammatory biomarkers and exercise capacity in adults with mildly elevated inflammation. Approximately 40 adult participants will be enrolled and randomly assigned to one of two intervention groups. Participants will consume their assigned fruit juice daily for approximately 2 weeks.

At baseline, participants will undergo study assessments including measurement of inflammatory status using a finger-stick blood sample for C-reactive protein (CRP) and assessment of exercise capacity using a standardized 6-minute walk test. Participants will then consume their assigned intervention daily during the study period. Follow-up assessments will be performed after the intervention period to evaluate changes in CRP and exercise capacity.

The primary objective of the study is to evaluate whether daily consumption of a fruit juice intervention is associated with changes in inflammatory biomarkers and exercise capacity in adults with mildly elevated inflammation. Changes in CRP and performance on the 6-minute walk test will be assessed before and after the intervention and compared between the two intervention groups.

The study is investigator-initiated and involves commercially available fruit juice products. The study is not conducted under an Investigational New Drug (IND) application or Investigational Device Exemption (IDE). The study has been reviewed and approved by the Northwell Institutional Review Board.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

40

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Beth Glace, MS
  • Número de teléfono: (212) 434-2717
  • Correo electrónico: bglace@northwell.edu

Copia de seguridad de contactos de estudio

  • Nombre: Ashley Giannita, BS, CCRC
  • Número de teléfono: 212-434-2744
  • Correo electrónico: agiannita@northwell.edu

Ubicaciones de estudio

    • New York
      • New York, New York, Estados Unidos, 10065
        • Reclutamiento
        • Nicholas Institute of Sports Medicine & Athletic Trauma (NISMAT)
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 65 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Participants ages 18-65 years old
  2. Physically and cognitively able to provide informed consent.
  3. Asymptomatic.
  4. Prior confirmed high normal or mild elevation of CRP (1.5- 9.9 mg/L)
  5. Able to perform a 30-second sit-to-stand test, a 6-minute walk test and a test of grip strength.
  6. Amenable to finger stick blood collection to determine CRP.
  7. Willing to consume 2- 8 oz juice beverages per day, containing 25 grams of sugar each, for 2 weeks.

Exclusion Criteria:

  1. Diagnosis of:

    1. Obstructive coronary artery disease (CAD).
    2. Currently or recently having exertional chest pain or pressure with high-risk history of CAD.
    3. History of heart failure.
    4. Obstructive or restrictive lung disease.
    5. Rheumatoid disorders that may increase CRP (lupus, RA or other rheumatic disorder).
    6. Thromboembolic disease requiring anticoagulation.
    7. Type 1 and insulin-dependent diabetes.
    8. Irritable bowel syndrome or Crohn's disease.
    9. Uncontrolled or untreated Type 2 Diabetes
  2. Participant is required to be on a stable dose of their maintenance medications for at least 1 month prior to participation in the study.

  3. Requiring oxygen supplementation during awake hours.

  4. Pregnancy or planning pregnancy during the duration of the study.

  5. Breastfeeding women.

  6. Score of 4 on any question in the DePaul Symptom Questionnaire - Post Exertional Malaise (DSQ-PEM).

  7. Participant, who in the medical opinion of the investigator team, is unsuitable to participate.

  8. Known allergy to apples or cherries.

  9. Current use of non-steroidal anti-inflammatory drugs (NSAIDs) listed below but not limited to:

    1. Aspirin
    2. Ibuprofen (Advil, Motrin)
    3. Naproxen (Aleve, Naprosyn)
    4. Ketoprofen (Orudis)
    5. Meclofenamate (Ponstel)
  10. The following steroids are excluded, but not limited to:

    1. Prednisolone
    2. Methylprednisolone
    3. Hydrocortisone
    4. Dexamethasme.
    5. Triamnicolone acetonide
    6. Budesonide
  11. Participants who have Limited English Proficiency (LEP) are excluded because study team members are not fluent in languages other than English, and the protocol relies heavily on direct verbal communication with participants throughout the study period. The protocol also involves detailed instructions, questionnaires and symptom reporting that require clear comprehension to ensure valid data collection and participant safety. Without certified translations, interpreter services and validated non-English study instruments, there is a risk that participants may not fully understand study procedures, potential risks or their rights as research participants. This could compromise informed consent, increase the likelihood of protocol deviations and place participants at undue risk.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Otro
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Active Fruit Juice Intervention

Participants assigned to this arm will consume the fruit juice intervention daily for approximately 2 weeks. The intervention is a commercially available fruit juice that can be purchased by consumers through retail and other commercial sources. The intervention is not an investigational drug or medical device.

Commercially available fruit juice administered as the dietary intervention. Participants will consume the assigned juice daily for approximately 2 weeks according to the study protocol. The specific product identity is not disclosed to participants as part of the study design.

Comparador activo: Control Fruit Juice Intervention

Participants assigned to this arm will consume the control fruit juice intervention daily for approximately 2 weeks. The intervention is a commercially available fruit juice that can be purchased by consumers through retail and other commercial sources. The intervention is not an investigational drug or medical device.

Commercially available fruit juice administered as the investigational dietary intervention. Participants will consume the assigned juice daily for approximately 2 weeks according to the study protocol. The specific product identity is not disclosed to participants as part of the study design.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Changes in the biomarker C-reactive protein (CRP) level
Periodo de tiempo: Baseline to post-intervention assessment (approx. 2-3 weeks after enrollment)

Change in C-reactive protein (CRP) level, measured in mg/L, from baseline to the post-intervention assessment following approximately 2 weeks of daily fruit juice consumption

Baseline to post-intervention assessment (approx. 2-3 weeks after enrollment)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in 6-Minute Walk Test Distance
Periodo de tiempo: Baseline to post-intervention assessment (approx. 2-3 weeks after enrollment)

Change in distance (m) walked during the 6-minute walk test from baseline to the post-intervention assessment following approximately 2 weeks of daily fruit juice consumption.

Baseline to post-intervention assessment (approx. 2-3 weeks after enrollment)
Change in Hand Grip Strength
Periodo de tiempo: Baseline to post-intervention assessment (approx. 2-3 weeks after enrollment)

Change in hand grip strength (kg) from baseline to the post-intervention assessment following approximately 2 weeks of daily fruit juice consumption. Hand grip strength is measured using a hand dynamometer.

Baseline to post-intervention assessment (approx. 2-3 weeks after enrollment)
Change in Grip Endurance
Periodo de tiempo: Baseline to post-intervention assessment (approx. 2-3 weeks after enrollment)

Change in grip endurance from baseline to the post-intervention assessment following approximately 2 weeks of daily fruit juice consumption. Grip endurance will be assessed at 50% of the mean maximal contraction force (min).

Baseline to post-intervention assessment (approx. 2-3 weeks after enrollment)
Change in Sit-to-Stand Test Performance
Periodo de tiempo: Baseline to post-intervention assessment (approx. 2-3 weeks after enrollment)

Change in number of repetitions from baseline to the post-intervention assessment following approximately 2 weeks of daily fruit juice consumption.

Baseline to post-intervention assessment (approx. 2-3 weeks after enrollment)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Christopher Tanayan, MD, Northwell Health

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

25 de septiembre de 2026

Finalización primaria (Estimado)

1 de septiembre de 2028

Finalización del estudio (Estimado)

1 de septiembre de 2028

Fechas de registro del estudio

Enviado por primera vez

23 de septiembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

1 de octubre de 2026

Publicado por primera vez (Actual)

7 de octubre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

13 de noviembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Individual participant data will not be shared with other researchers because there are no current plans to make the study data available for secondary research.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir